Know Cancer

forgot password

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Phase 2
18 Years
Open (Enrolling)
CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis

Thank you

Trial Information

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

This is a phase II study of Sunitinib in patients with recurrent or inoperable meningiomas.
An exploratory study will be performed for patients with recurrent hemangiopericytoma or
hemangioblastoma. There will be approximately 50 patients enrolled on this study (40
meningiomas and 10 hemangiopericytomas/hemangioblastomas). The treatment plan is to use
daily SU11248 at a dose of 50 mg, using the established schedule of 4 weeks of treatment
followed by two weeks of rest period, forming a six-week treatment cycle. A medical
professional will see each patient at least every six weeks while on the medication for
toxicity assessment and physical examination. Extent of disease evaluations will occur at
baseline, two weeks, twelve weeks, 24 weeks, and every twelve weeks thereafter. These
evaluations will include MRI of the brain (or CT head if a patient cannot undergo MRI) and
MR perfusion.

Inclusion Criteria:

- Histologically proven recurrent meningioma or intracranial hemangiopericytoma or
hemangioblastoma. This includes benign, atypical, or malignant meningioma; patients
with neurofibromatosis type 1 or 2 may participate.

- Patients with classic radiographic picture of meningioma may also enroll if not
surgically accessible. In this instance the patient must be reviewed at
multi-disciplinary brain tumor conference including neurosurgery and neuroradiology
to determine that the patient is appropriate for this study.

- Unequivocal evidence for tumor progression by MRI (or CT scan if MRI is
contraindicated). The scan must be performed within 14 days of registration.

- Steroids dosing - malignant meningiomas must be on stable dose for at least 5 days
prior to baseline imaging. For patients with benign or atypical meningiomas, stable
steroid doses are not required.

- Recent resection for recurrent tumor - patients will be eligible as long as they have
recovered from the effects of surgery and have residual disease that can be
evaluated. To best assess the extent of residual disease post-operatively, a CT/MRI
should be done no later than 96 hours in the immediate post-operative period or at
least 4 weeks post-operatively. If the 96 hour scan is more than 14 days before
registration, it should be repeated. Because Sunitinib is a VEGF inhibitor that can
carry many risks including thrombocytopenia, bleeding, hypertension, and stroke,
patients must wait at least 14 days after surgery, without complication, before they
may initiate study drug.

- Prior radiation therapy - patients may have been treated with standard external beam
radiation, interstitial brachytherapy, or radiosurgery in any combination. An
interval of ≥ 4 weeks (28 days) must have elapsed from the completion of radiation
therapy to study entry and there must be subsequent evidence of tumor progression.
Patients with prior interstitial brachytherapy or stereotactic radiosurgery must have
confirmation of true progressive disease rather than radiation necrosis based on PET,
MR spectroscopy or surgical documentation of disease.

- Patients who have not had prior surgery or radiotherapy for their meningioma will be
reviewed at multi-disciplinary brain tumor conference including neurosurgery and
radiation oncology to determine that the patient is appropriate for this study.

- Prior therapy: There is no limitation on the number of prior surgeries, radiation
therapy, radiosurgery treatments, or chemotherapy.

- All patients must sign an informed consent indicating that they are aware of the
investigational nature of the study. Patients must sign an authorization for the
release of their protected health information.

- Age ≥ 18 years old

- Karnofsky performance status ≥ 60%.

- ≥ 4 weeks since prior RT, stereotactic radiosurgery, or chemotherapy.

- Required Initial Laboratory Values (within 14 days of registration):

Absolute neutrophil count (ANC) ≥ 1,000/mm3

- Platelets ≥ 100,000/mm3

- hemoglobin ≥ 8gm/dl

- Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT])
and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) ≤
2.5 x local laboratory upper limit of normal (ULN)

- Creatinine ≤ 2.0 mg/dl

- PT, INR, and PTT ≤ 1.5 times institutional upper limits of normal

- Total serum bilirubin ≤ 1.5 - Patients with a history of NF may have other stable CNS
tumors, such as schwannoma, acoustic neuroma, or ependymoma, but ONLY if these
lesions have been stable in size for the preceding 6 months.

Exclusion Criteria:

- Patients with the history of any other cancer (except non-melanoma skin cancer or
carcinoma in-situ of the cervix, unless in complete remission and off all therapy for
the disease for a minimum of 3 years) are ineligible.

- Any prior TKI therapy (SU011248, Sorafenib, Semaxinib, Axitinib)

- Concomitant use of any other investigational drugs

- Concomitant use of enzyme-inducing anti-epileptic drugs.

- Concomitant use of St John's Wort.

- Any of the following within the 6 months prior to study drug administration:
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
graft, symptomatic congestive heart failure, cerebrovascular accident or transient
ischemic attack, or pulmonary embolism.

- Ongoing cardiac dysrhythmias of NCI CTCAE Version 3.0 grade ≥ 2.

- Prolonged QTc interval on baseline EKG (>450 msec for males and >470 msec for

- Uncontrolled hypertension (>150/100 mm Hg despite optimal medical therapy). Patients
are excluded if they have an elevated diastolic, an elevated systolic, or both.

- History of intracranial hemorrhage.

- Pre-existing thyroid abnormality, with thyroid function tests that cannot be
maintained in the normal range with medication.

- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
(AIDS)-related illness or other active infection.

- Concurrent treatment on another clinical trial. Supportive care trials or
non-treatment trials, e.g. QOL, are allowed.

- Ongoing treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg
daily for thromboembolic prophylaxis is allowed).

- Pregnancy or breast-feeding. Patients must be surgically sterile, postmenopausal, or
agree to use effective contraception during the period of therapy. The definition of
effective contraception will be based on the judgment of the principal investigator
or a designated associate. Male patients must be surgically sterile or agree to use
effective contraception. Women of childbearing potential must have a negative B-HCG
pregnancy test documented within 14 days prior to registration.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate the activity of sunitinib in patients with recurrent meningiomas as measured by 6-month progression-free survival.

Outcome Time Frame:

1.5 years

Safety Issue:


Principal Investigator

Thomas Kaley, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

October 2007

Completion Date:

October 2012

Related Keywords:

  • CNS Cancer
  • Meningioma
  • Intracranial Hemangiopericytoma
  • Hemangioblastoma
  • Neurofibromatosis
  • Sunitinib
  • Brain Cancer
  • CNS Cancer
  • meningioma
  • intracranial hemangiopericytoma
  • hemangioblastoma
  • malignant meningioma
  • neurofibromatosis
  • neurofibromatosis type 1
  • neurofibromatosis type 2
  • 07-135
  • Hemangiopericytoma
  • Meningioma
  • Neurofibromatoses
  • Neurofibromatosis 1
  • Osteitis Fibrosa Cystica
  • Central Nervous System Neoplasms
  • Hemangioblastoma



Memorial Sloan-Kettering Cancer Center New York, New York  10021
University of Pittsburgh Medical Center Pittsburgh, Pennsylvania  15213
Dana Farber Cancer Institute Boston, Massachusetts  02115
Memorial Sloan-Kettering Cancer Center at Commack Commack, New York  11725
Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey  
University of Virginia Health Science Center Charlottesville, Virginia  22908